YK012 for B-cell non-Hodgkin lymphoma after prior treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have a type of B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments (including rituximab)
- You have at least one tumor that can be measured on a CT scan
- You have not had CAR-T cell therapy, a stem cell transplant, or an organ transplant
- You do not have serious heart problems, active infections, or lymphoma that has spread to your brain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests an investigational pill (SHR2554) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if the pill can shrink the lymphoma and help control the disease.
This trial tests a new drug, YK012, for people with a certain kind of B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not gotten better after standard therapies. It aims to see if the drug is safe and works against these leukemia cells that have the CD19 marker.
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.